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Don’t sugar coat it: the effects of 
gestational diabetes on the 
placental vasculature
The placenta is a temporary organ, which facilitates the exchange of nutrients, waste and gases between 
the maternal and fetal circulatory systems. To perform its role, the placenta is a villous structure, which 
branches to cover a large surface area. In gestational diabetes (GDM), a major complication that 
affects otherwise healthy pregnancies, the placenta displays aberrant vasculature, including altered 
vascularization, villous immaturity, and endothelial dysfunction. Several contributors including 
reactive oxygen species (ROS), advanced glycation end products (AGEs) and the dysregulation of key 
angiogenic factors have been attributed to vascular dysfunction in GDM.
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Within the vascular structure of the placenta, the 
chorionic villi contain the fetal capillaries. These villi 
are bathed in maternal blood, within the intervillous 
space, and are the site of maternal/fetal exchange. 
In addition to vascular cells, syncytiotrophoblast 
and cytotrophoblast cells make up the trophoblast 
compartment of the placenta (see Table  1 for 
definitions). The syncytiotrophoblast is a multinucleated 
syncytium, in contact with the maternal blood. The 
syncytium has several functions: it not only serves as 
the transporting epithelium of the placenta but is also 
responsible for protecting the fetus from the maternal 
immune system and for the endocrine functions of 
the placenta, releasing hormones and growth factors 
important for placental development and maintaining 
pregnancy. Maintenance and expansion of the 
syncytiotrophoblast over pregnancy is provided by 
continuous proliferation, differentiation and fusion of 
the underlying cytotrophoblasts. As the trophoblast 
stem cell population of the placenta, cytotrophoblasts 
also differentiate into extravillous trophoblasts which 
migrate into the maternal decidua to remodel the 
maternal spiral arteries, regulating the maternal blood 
flow to the placenta. Beneath the cytotrophoblasts, 
within the villous core, lie several stromal cells, 
including fibroblasts, placental macrophages, known as 
Hofbauer cells, and placental mesenchymal stem cells 
which differentiate into many cell lineages, including 
endothelial and smooth muscle cells which form the 
blood vessels in the placenta (Figure 1).
Placental vascular development
Villous development relies heavily on vasculogenesis, the 
de novo formation of blood vessels, and angiogenesis, the 
branching of existing vessels. The process begins with 
the primitive mesenchymal villi that promote villous 
proliferation, mediated by the syncytiotrophoblast. 
These villi become tertiary villi through the growth of 
endothelial cell cords, via vasculogenesis. These cell 
cords develop a lumen and give rise to the first fetal 
capillaries. Once vasculogenesis has progressed and 
a primitive capillary network has formed, shown in 
Figure 2, the process of angiogenesis can begin, usually 
around 32 days after conception. Angiogenesis is 
dependent on trophoblast sprouting and proliferation 
allowing existing vessels to branch or elongate. This 
vast network of capillaries developed by these processes 
forms the chorionic villi.
Several pro- and anti- angiogenic factors are 
responsible for regulating angiogenesis and vascular 
development in the placenta. VEGF is one of the most 
essential growth factors responsible for regulating 
angiogenesis, and there are several forms of the VEGF 
receptor including VEGFR1, VEGFR2 and VEGFR3. 
Placental growth factor (PlGF) is also a member of the 
VEGF family and controls trophoblast proliferation and 
differentiation. It is also thought to initiate angiogenesis 
by either displacing VEGF from the VEGFR1, increasing 
the availability of VEGF that can bind to VEGFR2 or 
acting on VEGFR1 receptors and eliciting intracellular 
signals through this receptor. While VEGF and PlGF 
elicit pro- angiogenic responses in the placenta, the 
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acting as a VEGF and PlGF antagonist by blocking their 
binding to their receptors. Similarly, fibroblast growth 
factors (FGFs) are highly abundant in the placenta and 
are known to be important in trophoblast migration, 
self- renewal, and invasion. Particularly, FGF2 is known 
to play a significant role in placental angiogenesis and 
placental vascular growth throughout gestation.
In several complications of pregnancy, including 
gestational diabetes (GDM), there is villous immaturity 
and changes to placental vascularization and 
endothelial dysfunction are observed. This placental 
vascular dysfunction can compromise nutrient and 
waste exchange between the mother and the fetus, 
leading to placental insufficiency, where the placenta 
cannot fully support the developing fetus.
Gestational diabetes
GDM is one of the most common complications 
of otherwise healthy pregnancies, in which women 
without pre- existing diabetes develop a state of chronic 
hyperglycaemia during pregnancy. This metabolic 
condition occurs as a result of ‘diabetogenic’ changes 
in pregnancy, in which an array of contributory 
mechanisms elevate maternal glucose levels for fetal 
consumption. In the UK alone, GDM is diagnosed in 
up to 16% of pregnancies and prevalence is increasing 
in association with the rising prevalence of obesity. 
However, this worldwide problem has even higher 
rates of prevalence in developing countries, such that 
in the Punjab region of India, GDM has a reported 
prevalence of up to 35%.
There are a plethora of peri- natal complications 
that arise in poorly controlled GDM; most notably, 
infants can be born large for gestational age (LGA), 
predisposing to multiple difficulties during birth 
including shoulder dystocia, newborn asphyxia, and 
requirement for an emergency Caesarean section. 
Furthermore, infants born to GDM mothers also 
have a higher prevalence of respiratory distress 
syndrome due to hyperglycaemia- induced delay in 
fetal lung maturation. There is also the risk of neonatal 
hypoglycaemia, which can be easily rectified, but failure 
to diagnose promptly can produce seizures and rarely 
fatality. In addition to the short- term consequences, 
exposure to a GDM environment in utero is associated 
with several biochemical alterations in the fetus that 
elevates long- term cardiometabolic risks for baby, 
indicating the public health burden of this condition 
may extend beyond our initial expectations.
Complications are not only restricted to the fetus, 
with maternal consequences at birth from delivering 
LGA infants, an elevated risk of pre- eclampsia and 
meta- analysis data indicating the mother’s lifetime risk 
of a type 2 diabetes mellitus diagnosis was above 50%. 
Aside from this, these women are also at a twofold 
Table 1. 
Placental structure/cell type Definition
Chorionic villi Functional units of the placenta, which contain the fetal capillaries and are bathed in 
maternal blood
Cytotrophoblast Proliferate, differentiate and fuse to form the overlying syncytiotrophoblast. Also 
differentiate into extravillous trophoblasts
Extravillous trophoblast Invasive cytotrophoblasts, which remodel the maternal spiral arteries to regulate maternal 
blood flow to the placenta
Hofbauer cells Placental macrophages
Intervillous space The space between the chorionic villi, which contains maternal blood
Maternal decidua The maternal part of the placenta
Maternal spiral arteries Provide maternal blood to the placenta in the intervillous space
Placental mesenchymal stem cells Mesenchymal stem cells of the placenta, which are multipotent and can differentiate into 
many cell lineages, including endothelial and smooth muscle cells
Syncytiotrophoblast Multi- nucleated syncytium (single- cell layer). It is the outer layer of the chorionic villi 
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high risk of cardiovascular events post- partum than 
mothers without GDM, regardless of their diabetes 
status. Comparative to the available information on 
peri- natal complications, the mechanisms by which 
these long- term maternal and fetal cardiometabolic 
complications arise are not fully understood. However, 
it is thought to link to biochemical alterations in the 
placenta. The distinct association between GDM 
pregnancies and transgenerational metabolic disease 
proposes that the epigenetic alterations observed in 
type 2 diabetes mellitus may occur in mothers with 
GDM. In turn, alterations may cross the placenta and 
induce fetal epigenetic changes.
Placental vascular dysfunction in GDM
Due to the constituently active placental growth and 
the mediation of angiogenesis by multiple complex 
biological processes, the placenta is very vulnerable 
to alteration in maternal and fetal metabolic function. 
Principally, in women with poorly controlled GDM 
the placenta has several changes, particularly in the 
vasculature. Microscopic analysis revealed vascular 
morphological changes of fibrinoid necrosis and villous 
oedema. Furthermore, several studies have reported 
hypervascularization in GDM placentas, whereas 
others have reported hypovascularization. These 
contradicting findings on placental vascularization in 
GDM are likely a result of other underlying factors, 
such as maternal obesity or levels of glycaemic control 
achieved or, of particular note, the degree of endothelial 
dysfunction.
Figure 1. Structure of the placenta and its vasculature. 
Maternal uterine arteries supply oxygenated blood to the 
intervillous space, for the transport of oxygen and nutrients 
to the fetal circulation. The umbilical cord connects the 
placenta to the fetus, with the umbilical vein delivering 
the oxygenated and nutrient- rich blood to the fetus. The 
umbilical arteries carry deoxygenated blood to the placenta, 
for waste and carbon dioxide to be removed by the maternal 
veins. Inset: Schematic representing a cross section of the 
placental chorionic villi, containing the trophoblast layers 
(syncytiotrophoblast and cytotrophoblast), fetal blood 
vessels and placental mesenchymal stem cells. Other stromal 
cells are also present within the placental villi, including 
Hofbauer cells (placental macrophages) and fibroblasts. 
Figure created with Biorender.com.
Figure 2. Development of the placental vasculature. Villous development is dependent on the processes of vasculogenesis 
and angiogenesis. During vasculogenesis, mesenchymal stem cells differentiate and form endothelial cell cords, which 
develop into fetal capillaries. Once the capillary network has formed, the sprouting and elongation of existing vessels occurs 
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Molecular and biochemical pathways responsible for 
endothelial dysfunction in GDM
Whilst the exact underlying molecular pathways of 
hyperglycaemia- induced complications in GDM are 
unclear, patients with diabetes outside of pregnancy 
display endothelial dysfunction which is partially 
responsible for elevating their cardiometabolic disease 
risk. Endothelial dysfunction is characterized by an 
imbalance in the endothelium- derived vasodilating 
and vasoconstricting factors, thus predisposing to 
hypertension and atherosclerosis. To determine the 
presence of this association in GDM, human umbilical 
vein endothelial cells (HUVECs) were exposed to the 
chronic hyperglycaemia of GDM and have been seen 
to consequently display insulin insensitivity. As insulin 
acts as an activator of nitric oxide (NO) release, a potent 
vasodilator, this identifies one contributor pathway to 
the endothelial dysfunction of GDM. Similarly, insulin 
is required for the uptake of L- arginine, the substrate 
for NO synthase, and therefore insulin insensitivity 
impedes not only NO release but also NO synthesis. 
Upon further analysis, the protein kinase C (PKC) 
pathway has also been linked to deleterious changes in 
NO production in the placentas of GDM pregnancies, 
supported further by surrounding literature that found 
pathological vascular changes in GDM can be reversed 
with inhibition of the PKC pathway. Identifying 
therapeutic targets for this endothelial dysfunction 
may be essential to reducing placental changes and 
subsequent pathological fetal growth.
A secondary pathway to endothelial dysfunction in 
GDM is mediated by hyperglycaemia- induced changes 
including reactive oxygen species (ROS). Elevated ROS 
production is theorized to be of particular importance 
in vascular remodelling, and through epigenetic 
activity enhances the transcription of a multitude of 
pro- inflammatory mediators, including intracellular 
adhesion molecule 1, interleukin-6, and tumour necrosis 
factor-α, which collectively promote endothelial 
dysfunction. Alongside this, ROS can increase 
mitochondrial membrane permeability which facilitates 
the release of further ROS from the mitochondria into the 
cytosol. Release of mitochondrial ROS is accompanied 
by mitochondrial DNA, leaving it vulnerable to damage 
that can produce further mitochondrial dysfunction. 
Hyperglycaemia is responsible not only for ROS 
production, but also for advanced glycation end 
products (AGEs). These compounds have been observed 
to induce endothelial cell toxicity, and association 
between progression of cardiovascular disease and AGEs 
is evident in the existing literature. An overview of the 
plethora of contributors to endothelial dysfunction in 
GDM is outlined in Figure 3.
The imbalance between pro- and anti-angiogenic 
factors in GDM
Several of the angiogenic factors, responsible for 
regulating placental vascular development, have been 
reported to be altered in GDM, within the maternal 
circulation, cord blood and placenta. For example, 
Figure 3. Diagrammatic representation of a plethora of contributors to endothelial dysfunction in gestational diabetes 
mellitus. GDM = gestational diabetes mellitus. DAG = diacylglycerol. PKC = protein kinase C. NO = nitric oxide. AGE = 
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concentrations of the anti- angiogenic factor sFlt1 are 
known to be increased in the maternal circulation 
in GDM. The anti- angiogenic effect elicited by sFlt1 
can alter endothelial integrity and increase vascular 
permeability, which parallels the endothelial dysfunction 
observed in GDM.
In one study an increase in FGF2 was observed 
in maternal serum, cord serum and amniotic 
fluid in pregnancies complicated by maternal 
diabetes, including GDM. Interestingly, the FGF2 
concentrations were correlated with fetal and placental 
weight, proposing that FGF2 may also contribute to 
the development of LGA and abnormal fetal growth 
in GDM pregnancies. In one in vitro study, FGF2 
and VEGF significantly increased the proliferation 
of HUVECs from normal and GDM pregnancies. 
However, in GDM HUVECs, at higher concentrations 
of FGF2, cell proliferation was significantly lower 
than in HUVECs from normal pregnancies, further 
demonstrating potential endothelial dysfunction in 
GDM. Similar results were observed when HUVECs 
from normal pregnancies were treated with high 
glucose, proposing maternal hyperglycaemia as a causal 
factor. In this study, both FGF2 and VEGF were shown 
to induce ERK1/2 phosphorylation, and high glucose 
treatment inhibited FGF2- induced phosphorylation. 
This suggests a role of FGF2 and ERK1/2 in endothelial 
dysfunction induced by hyperglycaemia in women 
with GDM.
These aforementioned angiogenic factors can be 
released from the villous trophoblast of the placenta and 
elicit a paracrine function on neighbouring endothelial 
cells. Term placental trophoblasts isolated from GDM 
placentas were shown to have increased expression 
levels of anti- angiogenic, Angiopoietin-2 (ANGPT2) 
and KISS1 metastasis suppressor (KISS1), as well as pro- 
angiogenic, hepatocyte growth factor (HGF) and PlGF. 
Many in vitro studies have also demonstrated that glucose 
can alter the trophoblast secretome, demonstrating the 
contribution of maternal hyperglycaemia to placental 
vascular dysfunction in GDM. High glucose treatment 
in cultured trophoblast cells has been found to down- 
regulate pro- angiogenic factors, VEGF and PlGF, and 
upregulate anti- angiogenic factors, sEndoglin (sEng) 
and sFlt1, in addition to altered levels of inflammatory 
cytokines and chemokines. In other studies, PKC was 
shown to increase sFlt1 secretion from trophoblasts, 
suggesting the PKC pathway is responsible for this 
alteration in sFlt1 and in turn impaired angiogenesis 
in the placenta. Overall, the altered levels of these 
angiogenic factors in GDM demonstrate how an 
imbalance may lead to altered pathways and placental 
vascular and endothelial dysfunction in this disease.
Conclusions and future directions
Complications associated with GDM have been linked 
to aberrant placental vasculature, and particularly the 
increased long- term risk of cardiometabolic disease for 
the mother and baby has been attributed to endothelial 
dysfunction. As a myriad of factors are thought to 
contribute to this placental vascular dysfunction 
in GDM, including angiogenic factors, ROS, pro- 
inflammatory cytokines and AGEs, understanding 
the altered vasculature in GDM is incredibly complex, 
and the interaction between these factors needs to be 
investigated further. Additionally, other studies have 
reported the potential contribution of extracellular 
vesicles, and non- coding RNAs, such as micro- RNAs 
(miRNAs). Collectively, these markers may also pose 
as potential biomarkers for GDM diagnosis and its 
associated complications. For example, identifying 
markers of persistent endothelial dysfunction may 
in future be utilized to screen women with a history 
of GDM and identify those in the early stages on the 
pathway to cardiometabolic disorders. With this in 
mind, optimal follow- up for those deemed most at risk, 
including infants, may allow for prevention of future 
disease to minimize the burden of GDM.■
Further Reading
• Chow, R.P., Zhao, J. and Yu, J. (2018). PKC modulates sFlt1 production by human placental trophoblasts in response to 
oxidized LDL. Diabetes. 67 (Supplement 1), 1399- P. DOI:10.2337/db18-1399-P
• Han, C.S., Herrin, M.A., Pitruzzello, M.C., et al. (2015). Glucose and metforminmodulate human first trimester 
trophoblastfunction: A model and potential therapy fordiabetes- associated uteroplacental insufficiency. Am. J. 
Reprod. Immunol. 73 362–371. DOI: 10.1111/aji.12339
• Hiden, U., Lassance, L., Tabrizi, N.G., et al. (2012). Fetal insulin and IGF- II contribute to gestational diabetes mellitus 
(GDM)- associated up- regulation of membrane- type matrix metalloproteinase 1 (MT1- MMP) in the human feto- placental 







K user on 26 April 2021
39 April 2021 © The Authors. Published by Portland Press Limited under the Creative Commons Attribution License 4.0 (CC BY- NC- ND)
Diabetes
Further Reading
• Hill, D.J., Tevaarwerk, G.J.M., Caddell, C., et al. (1995). Fibroblast growth factor 2 is elevated in term maternal and cord 
serum and amniotic fluid in pregnancies complicated by diabetes: Relationship to fetal and placental size. J. Clin. 
Endocrinol. Metab. 80, 2626–2632. DOI: 10.1210/jcem.80.9.7673405
• Leach, L., Taylor, A. and Sciota, F. (2009). Vascular dysfunction in the diabetic placenta: causes and consequences. J. 
Anat. 215, 69–76. DOI: 10.1111/j.1469-7580.2009.01098.x
• Loegl, J., Nussbaumer, E., Cvitic, S., et al. (2017). GDM alters paracrine regulation of feto- placental angiogenesis via the 
trophoblast. Lab. Invest. 97, 409–418. DOI: 10.1038/labinvest.2016.149
• Moore, T.R. (2010). Fetal exposure to gestational diabetes contributes to subsequent adult metabolic syndrome. Am. J. 
Obstet. Gynecol. 202, 643–649. DOI: 10.1016/j.ajog.2010.02.059
• Sobrevia, L., Nadal, A., Yudilevich, D.L. and Mann, G.E. (1996). Activation of L- arginine transport (system y+) and nitric 
oxide synthase by elevated glucose and insulin in human endothelial cells. J. Physiol. 490, 775–781. DOI: 10.1113/
jphysiol.1996.sp021185
• Zhou, J., Ni, X., Huang, X., et al. (2016). Potential role of hyperglycemia in fetoplacental endothelial dysfunction in 
gestational diabetes mellitus. Cell. Physiol. Biochem. 39, 1317–1328. DOI: 10.1159/000447836
• Zhu, Y. and Zhang, C. (2016). Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global 
Perspective. Curr. Diab. Rep. 16, 7. DOI: 10.1007/s11892-015-0699-x
Abigail Byford is in her second year of PhD study at the University of Leeds and is funded by a 4- year BHF PhD 
programme studentship. Abigail works in the Forbes/Scott groups investigating the contribution of maternal 
glucose fluctuations to placental vascular dysfunction and altered fetal growth in pregnancies complicated by 
gestational diabetes. Email: bs14ab@leeds.ac.uk
Chloe Baird- Rayner is an undergraduate medical student at the University of Sheffield and is currently 
intercalating on the BSc Cardiovascular Medicine course at the University of Leeds. Chloe is undertaking 
her research project in the Forbes lab group investigating the impact of maternal glucose fluctuations on 
human placental gene expression and vascular development. Email: um20cpeb@leeds.ac.uk
Karen Forbes is an MRC New Investigator Research Grant holder and an Associate Professor of Molecular 
Endocrinology and Reproduction at University of Leeds. Her research group is focussed on understanding how 
the maternal environment (e.g., diabetes status, BMI, diet or circulating RNA molecules) influences events in 
the placenta, leading to adverse pregnancy outcomes and to subsequent programming of the offspring for 
adulthood diseases. She has a programme of research spanning from understanding the basic mechanisms 








K user on 26 April 2021
